We conduct a meticulous assessment of unmet clinical needs and market competition, both domestically and internationally, to launch projects with distinct differentiation in targets and technologies. We focus primarily on cancers with high incidence and mortality rates, immunological disorders, and metabolic diseases.
Technology Innovation
By integrating emerging technologies, such as next-generation kinase inhibitors, allosteric inhibition, synthetic lethality, PROTACs, and molecular glues, and based on well-defined mechanisms and high selectivity, we are committed to delivering potential drugs with superior efficacy and lower toxicity for clinical applications.
Platform System
Powered by AI technology, we maximize the reduction of development costs and the improvement of efficiency, and through a flexible and innovative operational model, we efficiently advance the development of our pipelines.
Recruiting non-small cell lung cancer patients with EGFR mutations
Indications: Advanced or metastatic non-small cell lung cancer with EGFR mutations
Investigational drug: PH009-1 tablets
Age requirement: ＞18 years old
Number of recruited subjects: no preset limit
Region: Guangdong/ Henan/ Shandong/ Tianjin/ Fujian/ Guangxi/ Hubei/ Shanghai/ Hunan/ Heilongjiang
